The pro-regenerative effects of HyperIL6 in drug induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling

  1. Jinrui Dong
  2. Sivakumar Viswanathan
  3. Eleonora Adami
  4. Sebastian Schafer
  5. Fathima F Kuthubudeen
  6. Anissa A Widjaja
  7. Stuart A Cook  Is a corresponding author
  1. Duke-National University of Singapore Medical School, Singapore
  2. National Heart Research Institute of Singapore, Singapore

Abstract

It is generally accepted that IL6-mediated STAT3 signaling in hepatocytes, mediated via glycoprotein 130 (gp130; IL6ST), is beneficial and that the synthetic IL6:IL6ST fusion protein (HyperIL6) promotes liver regeneration. Recently, autocrine IL11 activity that also acts via IL6ST but uses ERK rather than STAT3 to signal, was found to be hepatotoxic. Here we examined whether the beneficial effects of HyperIL6 could reflect unappreciated competitive inhibition of IL11-dependent IL6ST signaling. In human and mouse hepatocytes, HyperIL6 reduced N-acetyl-p-aminophenol (APAP)-induced cell death independent of STAT3 activation and instead, dose-dependently, inhibited IL11-related signaling and toxicities. In mice, expression of HyperIl6 reduced ERK activation and promoted STAT3-independent hepatic regeneration (PCNA, Cyclin D1, Ki67) following administration of either IL11 or APAP. Inhibition of putative intrinsic IL6 trans-signaling had no effect on liver regeneration in mice. Following APAP, mice deleted for Il11 exhibited spontaneous liver repair but HyperIl6, despite robustly activating STAT3, had no effect on liver regeneration in this strain. These data show that synthetic IL6ST binding proteins such as HyperIL6 can have unexpected, on-target effects and suggest IL11, not IL6, as important for liver regeneration.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Source data are provided with this paper.

Article and author information

Author details

  1. Jinrui Dong

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  2. Sivakumar Viswanathan

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  3. Eleonora Adami

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  4. Sebastian Schafer

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    Sebastian Schafer, is a co-inventor of the patent applications: WO/2017/103108 (Treatment of Fibrosis), WO/2018/109174 (IL11 Antibodies), WO/2018/109170 (IL11RA Antibodies), and US 2020/0262910 (Treatment of Hepatotoxicity). Is a co-founder and shareholder of Enleofen Bio PTE LTD..
  5. Fathima F Kuthubudeen

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    No competing interests declared.
  6. Anissa A Widjaja

    Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore, Singapore
    Competing interests
    Anissa A Widjaja, A.A.W is a co-inventor of the patent application: US 2020/0262910 (Treatment of Hepatotoxicity)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9404-7608
  7. Stuart A Cook

    CVMD, National Heart Research Institute of Singapore, Singapore, Singapore
    For correspondence
    stuart.cook@duke-nus.edu.sg
    Competing interests
    Stuart A Cook, S.A.C. is a co-inventor of the patent applications: WO/2017/103108 (TREATMENT OF FIBROSIS), WO/2018/109174 (IL11 ANTIBODIES), WO/2018/109170 (IL11RA ANTIBODIES), and US 2020/0262910 (Treatment of Hepatotoxicity). S.A.C. is a co-founder and shareholder of Enleofen Bio PTE LTD..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6628-194X

Funding

National Medical Research Council (NMRC/STaR/0029/2017)

  • Stuart A Cook

National Medical Research Council (NMRC Centre Grant to the NHCS)

  • Stuart A Cook

National Medical Research Council (MOH‐CIRG18nov‐0002)

  • Stuart A Cook

Medical Research Council (MRC-LMS)

  • Stuart A Cook

Goh Foundation

  • Stuart A Cook

Tanoto Foundation

  • Stuart A Cook

National Medical Research Council (NMRC/OFYIRG/0053/2017)

  • Anissa A Widjaja

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal studies were carried out in compliance with the recommendations in the Guidelines on the Care and Use of Animals for Scientific Purposes of the National Advisory Committee for Laboratory Animal Research (NACLAR). All experimental procedures were approved (SHS/2014/0925 and SHS/2019/1482) and conducted in accordance with the SingHealth Institutional Animal Care and Use Committee.

Copyright

© 2021, Dong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,365
    views
  • 258
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jinrui Dong
  2. Sivakumar Viswanathan
  3. Eleonora Adami
  4. Sebastian Schafer
  5. Fathima F Kuthubudeen
  6. Anissa A Widjaja
  7. Stuart A Cook
(2021)
The pro-regenerative effects of HyperIL6 in drug induced liver injury are unexpectedly due to competitive inhibition of IL11 signaling
eLife 10:e68843.
https://doi.org/10.7554/eLife.68843

Share this article

https://doi.org/10.7554/eLife.68843

Further reading

    1. Cell Biology
    Chengfang Pan, Ying Liu ... Changlong Hu
    Research Article

    Prostaglandin E2 (PGE2) is an endogenous inhibitor of glucose-stimulated insulin secretion (GSIS) and plays an important role in pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). This study aimed to explore the underlying mechanism by which PGE2 inhibits GSIS. Our results showed that PGE2 inhibited Kv2.2 channels via increasing PKA activity in HEK293T cells overexpressed with Kv2.2 channels. Point mutation analysis demonstrated that S448 residue was responsible for the PKA-dependent modulation of Kv2.2. Furthermore, the inhibitory effect of PGE2 on Kv2.2 was blocked by EP2/4 receptor antagonists, while mimicked by EP2/4 receptor agonists. The immune fluorescence results showed that EP1–4 receptors are expressed in both mouse and human β-cells. In INS-1(832/13) β-cells, PGE2 inhibited voltage-gated potassium currents and electrical activity through EP2/4 receptors and Kv2.2 channels. Knockdown of Kcnb2 reduced the action potential firing frequency and alleviated the inhibition of PGE2 on GSIS in INS-1(832/13) β-cells. PGE2 impaired glucose tolerance in wild-type mice but did not alter glucose tolerance in Kcnb2 knockout mice. Knockout of Kcnb2 reduced electrical activity, GSIS and abrogated the inhibition of PGE2 on GSIS in mouse islets. In conclusion, we have demonstrated that PGE2 inhibits GSIS in pancreatic β-cells through the EP2/4-Kv2.2 signaling pathway. The findings highlight the significant role of Kv2.2 channels in the regulation of β-cell repetitive firing and insulin secretion, and contribute to the understanding of the molecular basis of β-cell dysfunction in diabetes.

    1. Cell Biology
    Weihua Wang, Junqiao Xing ... Zhangfeng Hu
    Research Article

    Existence of cilia in the last eukaryotic common ancestor raises a fundamental question in biology: how the transcriptional regulation of ciliogenesis has evolved? One conceptual answer to this question is by an ancient transcription factor regulating ciliary gene expression in both uni- and multicellular organisms, but examples of such transcription factors in eukaryotes are lacking. Previously, we showed that an ancient transcription factor X chromosome-associated protein 5 (Xap5) is required for flagellar assembly in Chlamydomonas. Here, we show that Xap5 and Xap5-like (Xap5l) are two conserved pairs of antagonistic transcription regulators that control ciliary transcriptional programs during spermatogenesis. Male mice lacking either Xap5 or Xap5l display infertility, as a result of meiotic prophase arrest and sperm flagella malformation, respectively. Mechanistically, Xap5 positively regulates the ciliary gene expression by activating the key regulators including Foxj1 and Rfx families during the early stage of spermatogenesis. In contrast, Xap5l negatively regulates the expression of ciliary genes via repressing these ciliary transcription factors during the spermiogenesis stage. Our results provide new insights into the mechanisms by which temporal and spatial transcription regulators are coordinated to control ciliary transcriptional programs during spermatogenesis.